Early mechanical reperfusion through percutaneous coronary intervention (PCI) is the foundation of acute myocardial infarction (AMI) therapy. Over the past 2 decades, an enormous infrastructure has been developed to provide rapid access to the cardiac catheterization laboratory for patients presenting with AMI. In the creation of this ‘STEMI system of care’, mortality for patients presenting with AMI without cardiogenic shock (CS) has been driven to <2% [ ]. However, in those presenting with acute myocardial infarction and cardiogenic shock (AMICS), despite early reperfusion therapy, mortality is exponentially higher (~50%).